Cogent Biosciences announces planned 2024 milestones

Cogent Biosciences highlighted the company’s key 2024 milestones ahead of its presentation at J.P. Morgan’s 42nd annual healthcare conference. In 2024, the Company plans to achieve the following milestones: Bezuclastinib – Systemic Mastocytosis: Present data from the complete SUMMIT Part 1 trial in patients with Non-Advanced Systemic Mastocytosis at the 2024 American Academy of Allergy, Asthma & Immunology annual conference in February; Initiate SUMMIT Part 2 in 1H 2024; Finalize, including alignment with regulators, Cogent’s MS2D2, a novel patient reported outcomes tool designed to measure symptomatic severity and improvement for patients enrolled in the SUMMIT study. Complete enrollment in the registration-directed APEX Phase 2 trial in patients with Advanced Systemic Mastocytosis. Bezuclastinib – Gastrointestinal Stromal Tumors: Complete enrollment of global, randomized Phase 3 PEAK trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in imatinib-resistant GIST patients. CGT4859: Initiate Phase 1 trial of the first Cogent-discovered pipeline program, designed as a potent, selective, reversible FGFR2 inhibitor with best-in-class potential. Preclinical Pipeline: Initiate IND-enabling studies for lead candidate from potent, selective ErbB2 program, highlighted by potential best-in-class brain penetrant properties; Select lead candidate and initiate IND-enabling studies from ongoing PI3Kalpha program, designed to potently and selective target the H1047R driver mutation, which affects greater than30,000 cancer patients each year